Cary Street Partners Investment Advisory LLC Alkermes Plc. Transaction History

Cary Street Partners Investment Advisory LLC

$2.63 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$28.34 - $33.63 $7,226 - $8,575	255 Added 5.12%	5,232 $163,000
Q1 2023 May 12, 2023	BUY	$25.31 - $29.02 $68,286 - $78,295	2,698 Added 118.39%	4,977 $140,000
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $50,001 - $59,800	2,279 New	2,279 $59,000

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

Black Rock Inc. New York, NY

29.1M
Shares

$865 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$564 Million
0.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

13M
Shares

$386 Million
0.04% of portfolio
Wellington Management Group LLP Boston, MA

12.7M
Shares

$376 Million
0.06% of portfolio
State Street Corp Boston, MA

9.19M
Shares

$273 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cary Street Partners Investment Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cary Street Partners Investment Advisory LLC with notifications on news.

Account